A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions
Recurrent Calcium Oxalate Kidney Stone DiseaseElevated Urinary Oxalate Levels
Interventions
DRUG

Lumasiran

Lumasiran will be administered by SC injection.

DRUG

Placebo

Placebo will be administered by SC injection.

Trial Locations (31)

11530

Clinical Trial Site, Garden City

12208

Clinical Trial Site, Albany

27403

Clinical Trial Site, Greensboro

29405

Clinical Trial Site, North Charleston

30101

Clinical Trial Site, Acworth

33016

Clinical Trial Site, Hialeah

35233

Clinical Trial Site, Birmingham

46032

Clinical Trial Site, Carmel

55435

Clinical Trial Site, Edina

55905

Clinical Trial Site, Rochester

62301

Clinical Trial Site, Quincy

77054

Clinical Trial Site, Houston

79902

Clinical Trial Site, El Paso

89128

Clinical Trial Site, Las Vegas

91324

Clinical Trial Site, Northridge

94143

Clinical Trial Site, San Francisco

02114

Clinical Trial Site, Boston

Unknown

Clinical Trial Site, Brussels

Clinical Trial Site, Ghent

Clinical Trial Site, Kortrijk

Clinical Trial Site, Liège

Clinical Trial Site, Bologna

Clinical Trial Site, Pavia

Clinical Trial Site, Rome

Clinical Trial Site, Verona

Clinical Trial Site, Madrid

Clinical Trial Site, Bern

Clinical Trial Site, Lausanne

Clinical Trial Site, Zurich

Clinical Trial Site, Doncaster

Clinical Trial Site, Leeds

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY